Dare Bioscience earnings missed by $0.02, revenue fell short of estimates

Dare Bioscience (DARE) reported Q3 EPS of -$0.18, missing estimates by $0.02, and revenue of $47.63K, below the $1.82M consensus. The stock is down 27.81% in 3 months and 67.18% in 12 months. InvestingPro rates its financial health as 'fair performance'.

Original reporting
Published Nov 17, 2026, 12:37 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 1:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$DARE
Bearish
high confidence
Mentioned
$DARE
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$DAREBearishMed
01

Why it matters

The combination of an EPS miss and a far-below-consensus revenue figure is typically bearish for liquidity-constrained biotech names, especially when the article provides no offsetting positive catalyst like guidance or trial progress.

02

Market read

Traders can use the reported miss versus consensus to reassess near-term risk and expectations for subsequent updates.

03

What to watch

The article does not include guidance, cash runway, or management commentary, which are often more important than the headline revenue miss for biotech micro-caps.

Relevance 8/10Novelty 7/10Timing: post-earnings reaction context, published same day as the reported Q3 results

Background

The piece summarizes Dare Bioscience’s Q3 results versus analyst consensus and notes recent stock performance.

Company-level read

Ticker impact

$DAREBearishHigh confidence
Context

Dare Bioscience reported Q3 EPS of -$0.18, missing by $0.02, and revenue of $47.63K versus $1.82M consensus.

Expected impact

Likely downward pressure as the market reprices the company’s ability to generate revenue and meet expectations.

Evidence & confidence

The article provides the company’s own quarterly EPS and revenue versus consensus, which are direct drivers of post-earnings sentiment and positioning.

Market effects

Limited read-through to the broader biotech sector; this is a single micro-cap earnings miss with no stated sector-wide catalyst.

No clear regional spillover beyond small-cap biotech sentiment.

Minimal global relevance; the disclosure is company-specific.

Counterpoint

If the revenue miss reflects timing of milestone recognition rather than demand collapse, the stock could stabilize on any subsequent operational updates not covered here.

Key entities

  • Dare Bioscience

    NASDAQ-listed biotech issuer reporting Q3 EPS and revenue versus consensus.

Related articles

$DAREMed

Daré Bioscience Reports Third Quarter 2026 Financial Results and Highlights Commercial Execution and Pipeline Advancement

Dare Bioscience, Inc. (DARE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Daré Bioscience Reports Third Quarter 2026 Financial Results and Highlights Commercial Execution and Pipeline Advancement DARE to PLAY™ Sildenafil Cream prescription dispensing activities underway this month, with prescriptions written across 48 states and Washington

$DAREMedAI 8/10

Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting

Daré Bioscience (NASDAQ: DARE) will present Phase 1 data on its Sildenafil Cream at the SMSNA Annual Fall Scientific Meeting. The study showed lower systemic exposure compared to oral sildenafil, with no serious adverse events. The company is developing the cream as a potential treatment for female sexual arousal disorder (FSAD), for which there are currently no FDA-approved treatments.

$DAREMedAI 8/10

Daré Bioscience Reports Phase 1 Sildenafil Cream Data Showing Lower Systemic Exposure

Daré Bioscience (DARE) reported Phase 1 data for its Sildenafil Cream, showing lower systemic exposure than oral sildenafil. The study, published in Sexual Medicine, involved 62 healthy men and found significantly lower plasma concentrations for topical administration. The cream is being developed for women's sexual health. DARE stock is currently trading at $0.71, up 0.69%.